Lv4
690 积分 2020-10-02 加入
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
9天前
已完结
Marketing authorisations for unmet medical needs: A critical appraisal of regulatory pathways in the European Union
12天前
已完结
Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial
2个月前
已完结
Engineering CAR-T therapies for autoimmune disease and beyond
3个月前
已完结
In vivo CAR T cell generation to treat cancer and autoimmune disease
3个月前
已完结
PD-1, BTLA and TIGIT as therapeutic targets for rheumatic disease
3个月前
已完结
The dawn of ‘off-the-shelf’ B cell-depleting therapies for autoimmune diseases
3个月前
已完结
Bispecific and multispecific antibodies in oncology: opportunities and challenges
3个月前
已完结
FDA approves 100th small-molecule kinase inhibitor
3个月前
已完结
Key insights from ESMO Congress 2025
3个月前
已完结
皖公网安备34019202002308
